This is a summary of the European public assessment report (EPAR) for Azopt. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Azopt.
Therapeutic Indication
### Therapeutic indication Azopt is indicated to decrease elevated intraocular pressure in: - ocular hypertension; - open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.
Therapeutic Area (MeSH)
ATC Code
S01EC04
ATC Item
brinzolamide
Pharmacotherapeutic Group
Ophthalmologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| brinzolamide | N/A | 布林佐胺 |
EMA Name
Azopt
Medicine Name
Azopt
Aliases
N/A